{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:12:34Z","timestamp":1789668754525,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prior studies have demonstrated variation in surgical management of breast cancer. As randomized controlled trials have increasingly shown a limited survival advantage with surgery in stage IV breast cancer, the present study aimed to assess geographic and institutional variations in locoregional surgical management of de novo stage IV breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort analysis of 68,670 patients with de novo stage IV breast cancer from 2012 to 2021 using the National Cancer Database. The proportion of patients treated with surgical resection was compared between year of diagnosis, facility type, geographic region, and facility volume while controlling for demographic and clinical variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 17,620 patients (25.7%) with de novo stage IV breast cancer underwent breast, axillary, or metastatic site surgical resection. There was a statistically significant decrease from 27.4 to 15.0% in the proportion of patients undergoing primary tumor resection over the included timeframe (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). Significant variation was noted in the proportion of patients receiving primary tumor resection among geographic regions, ranging from 14.9 to 23.2% (Northeast and West,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). Patients treated at comprehensive community cancer centers were most likely to have primary site surgery, and those treated at academic centers (including National Cancer Institute\u2013designated comprehensive cancer centers) were least likely (22.1 vs. 16.7%, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Significant variation exists in locoregional surgical management of de novo stage IV breast cancer. Surgical intervention has decreased over time, but this study reveals that institutional and geographic factors are associated with the surgical management for these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20123-3","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T19:21:55Z","timestamp":1783797715000},"page":"9089-9101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Variation in Surgical Management of Stage IV Breast Cancer: Local\/Institutional and Regional Geographic Considerations"],"prefix":"10.1245","volume":"33","author":[{"given":"Shruti","family":"Zaveri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Whitham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anvy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushii","family":"Nadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Marilyn","family":"Leitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Farr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wooldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Froix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie K.","family":"Serres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"S3","key":"20123_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","volume":"10","author":"J O\u2019Shaughnessy","year":"2005","unstructured":"O\u2019Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(S3):20\u20139.","journal-title":"Oncologist."},{"key":"20123_CR2","unstructured":"Surveillance. Epidemiology aERSPwscgSSDISRP-U, Nov 2004 Sub (1973\u20132002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission. Surveillance, Epidemiology, and End Results Program"},{"issue":"3","key":"20123_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/SLA.0000000000002621","volume":"269","author":"WO Lane","year":"2019","unstructured":"Lane WO, Thomas SM, Blitzblau RC, et al. Surgical resection of the primary tumor in women with de novo stage IV breast cancer: contemporary practice patterns and survival analysis. Ann Surg. 2019;269(3):537\u201344.","journal-title":"Ann Surg."},{"issue":"1","key":"20123_CR4","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1038\/s41598-020-59908-1","volume":"10","author":"R Gera","year":"2020","unstructured":"Gera R, Chehade HELH, Wazir U, Tayeh S, Kasem A, Mokbel K. Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: a meta-analysis. Sci Rep. 2020;10(1):2952.","journal-title":"Sci Rep."},{"issue":"8","key":"20123_CR5","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1245\/s10434-007-9438-0","volume":"14","author":"J Gnerlich","year":"2007","unstructured":"Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988\u20132003 SEER data. Ann Surg Oncol. 2007;14(8):2187\u201394.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"20123_CR6","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1245\/s10434-012-2844-y","volume":"20","author":"JE Lang","year":"2013","unstructured":"Lang JE, Tereffe W, Mitchell MP, et al. Primary tumor extirpation in breast cancer patients who present with stage IV disease is associated with improved survival. Ann Surg Oncol. 2013;20(6):1893\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"20123_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/tbj.13005","volume":"24","author":"NA Vohra","year":"2018","unstructured":"Vohra NA, Brinkley J, Kachare S, Muzaffar M. Primary tumor resection in metastatic breast cancer: a propensity-matched analysis, 1988\u20132011 SEER data base. Breast J. 2018;24(4):549\u201354.","journal-title":"Breast J."},{"issue":"4","key":"20123_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/tbj.13296","volume":"25","author":"C Arciero","year":"2019","unstructured":"Arciero C, Liu Y, Gillespie T, Subhedar P. Surgery and survival in patients with stage IV breast cancer. Breast J. 2019;25(4):644\u201353.","journal-title":"Breast J."},{"issue":"11","key":"20123_CR9","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1158\/1055-9965.EPI-22-0495","volume":"31","author":"ED Duchesneau","year":"2022","unstructured":"Duchesneau ED, Jackson BE, Webster-Clark M, et al. The timing, the treatment, the question: comparison of epidemiologic approaches to minimize immortal time bias in real-world data using a surgical oncology example. Cancer Epidemiol Biomarkers Prev. 2022;31(11):2079\u201386.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"6","key":"20123_CR10","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jamcollsurg.2021.08.686","volume":"233","author":"A Soran","year":"2021","unstructured":"Soran A, Ozmen V, Ozbas S, et al. Primary surgery with systemic therapy in patients with de novo stage IV breast cancer: 10-year follow-up; protocol MF07-01 randomized clinical trial. J Am Coll Surg. 2021;233(6):742-751.e745.","journal-title":"J Am Coll Surg."},{"issue":"13","key":"20123_CR11","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","volume":"16","author":"R Badwe","year":"2015","unstructured":"Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16(13):1380\u20138.","journal-title":"Lancet Oncol."},{"issue":"6","key":"20123_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/SLA.0000000000002771","volume":"269","author":"F Fitzal","year":"2019","unstructured":"Fitzal F, Bjelic-Radisic V, Knauer M, et al. Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial. Ann Surg. 2019;269(6):1163\u20139.","journal-title":"Ann Surg."},{"issue":"18_suppl","key":"20123_CR13","doi-asserted-by":"publisher","first-page":"LBA2","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA2","volume":"38","author":"SA Khan","year":"2020","unstructured":"Khan SA, Zhao F, Solin LJ, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN research group (E2108). J Clin Oncol. 2020;38(18_suppl):LBA2\u2013LBA2.","journal-title":"J Clin Oncol."},{"issue":"5","key":"20123_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41416-025-03097-z","volume":"133","author":"T Shien","year":"2025","unstructured":"Shien T, Hara F, Aogi K, et al. Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial. Br J Cancer. 2025;133(5):625\u201332.","journal-title":"Br J Cancer."},{"issue":"4","key":"20123_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.suc.2018.03.012","volume":"98","author":"M Teshome","year":"2018","unstructured":"Teshome M. Role of operative management in stage IV breast cancer. Surg Clin North Am. 2018;98(4):859\u201368.","journal-title":"Surg Clin North Am."},{"issue":"24","key":"20123_CR16","doi-asserted-by":"publisher","first-page":"5526","DOI":"10.1200\/JCO.2005.06.217","volume":"23","author":"SJ Katz","year":"2005","unstructured":"Katz SJ, Lantz PM, Janz NK, et al. Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol. 2005;23(24):5526\u201333.","journal-title":"J Clin Oncol."},{"issue":"7","key":"20123_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/01.mlr.0000215893.01968.f1","volume":"44","author":"ST Hawley","year":"2006","unstructured":"Hawley ST, Hofer TP, Janz NK, et al. Correlates of between-surgeon variation in breast cancer treatments. Med Care. 2006;44(7):609\u201316.","journal-title":"Med Care."},{"issue":"5","key":"20123_CR18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.amjsurg.2017.07.008","volume":"214","author":"AS Chiu","year":"2017","unstructured":"Chiu AS, Thomas P, Killelea BK, Horowitz N, Chagpar AB, Lannin DR. Regional variation in breast cancer surgery: results from the national cancer database (NCDB). Am J Surg. 2017;214(5):907\u201313.","journal-title":"Am J Surg."},{"issue":"1","key":"20123_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10549-021-06155-1","volume":"188","author":"I Dankwa-Mullan","year":"2021","unstructured":"Dankwa-Mullan I, George J, Roebuck MC, et al. Variations in breast cancer surgical treatment and timing: determinants and disparities. Breast Cancer Res Treat. 2021;188(1):259\u201372.","journal-title":"Breast Cancer Res Treat."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20123-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20123-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20123-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:53:08Z","timestamp":1789667588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20123-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20123"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20123-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflicts of interest were reported by any of the study\u2019s authors.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}